{"id":650,"date":"2015-07-30T11:03:04","date_gmt":"2015-07-30T05:33:04","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=650"},"modified":"2024-09-18T15:21:30","modified_gmt":"2024-09-18T09:51:30","slug":"systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","title":{"rendered":"Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015"},"content":{"rendered":"<p><strong>Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old<\/strong>, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA.<\/p>\n<p>It is an <strong>autoimmune disorder<\/strong> when body\u2019s own immune cell starts attacking healthy cells. This results in inflammation. It is also known as &#8220;systemic onset juvenile rheumatoid arthritis&#8221;It makes the joints inflamed and stiff for more than six weeks.<\/p>\n<p><strong>DelveInsight<\/strong> report on Systemic Juvenile Idiopathic Arthritis provides comparative study of drugs under development. The report provides assessment of <strong><em>Tofacitinib<\/em> pipeline drug by <em>Pfizer<\/em><\/strong> <strong>Phase III.<\/strong> In addition to this, the report imparts information on several other drugs as well.<\/p>\n<p><em><strong>Key Highlights of Report:<\/strong><\/em><\/p>\n<ul>\n<li>Comprehensive insights about pipeline drugs across this indication<\/li>\n<li>Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages<\/li>\n<li>Therapeutics assessment by monotherapy and combination products and molecule type drug information<\/li>\n<li>Companies involved in therapeutic development of the products<\/li>\n<li>Discontinued and dormant products<\/li>\n<\/ul>\n<p>DelveInsight is offering the Report at a price of <em><strong>US 1,250<\/strong> <\/em>as a single user license, <em><strong>USD 2,500<\/strong> <\/em>as a site license and <em><strong>USD 4,000<\/strong> <\/em>as a Global\/Enterprise License.<\/p>\n<p><strong>About Us:<\/strong><\/p>\n<p>DelveInsight is a leading Business Consulting and Market Research Firm.&nbsp; We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing <em><strong>custom research services in coherence with interest area of the clients.<\/strong><\/em><\/p>\n<p>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[204,476,481,485,539],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-650","post","type-post","status-publish","format-standard","hentry","category-articles","tag-delveinsight","tag-phase-iii-pipeline","tag-pipeline-drugs","tag-pipeline-reports","tag-sjia","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Systemic Juvenile Idiopathic Arthritis Therapeutic Assessment<\/title>\n<meta name=\"description\" content=\"The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Systemic Juvenile Idiopathic Arthritis Therapeutic Assessment\" \/>\n<meta property=\"og:description\" content=\"The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-30T05:33:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:51:30+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Systemic Juvenile Idiopathic Arthritis Therapeutic Assessment","description":"The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","og_locale":"en_US","og_type":"article","og_title":"Systemic Juvenile Idiopathic Arthritis Therapeutic Assessment","og_description":"The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA...","og_url":"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-30T05:33:04+00:00","article_modified_time":"2024-09-18T09:51:30+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","url":"https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015","name":"Systemic Juvenile Idiopathic Arthritis Therapeutic Assessment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2015-07-30T05:33:04+00:00","dateModified":"2024-09-18T09:51:30+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/systemic-juvenile-idiopathic-arthritis-pipeline-insights-2015"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase III Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SJIA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Phase III Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Drugs<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Reports<\/span>","<span class=\"advgb-post-tax-term\">SJIA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jul 30, 2015","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jul 30, 2015 11:03 am","modified":"Updated on Sep 18, 2024 3:21 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=650"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/650\/revisions"}],"predecessor-version":[{"id":29635,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/650\/revisions\/29635"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=650"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=650"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}